BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies, a medical technology firm, has entered into three new evaluation agreements for its PURE EP™ System, reducing assessment cycles to 90 days. This shift follows successful evaluations in 2020 and aims to facilitate rapid commercialization. The new clinical sites, including prestigious hospitals like New York-Presbyterian and Michigan Medicine, will enhance the system's deployment. Over 500 patient cases have already been recorded using the PURE EP™ System. The company anticipates increased activity in 2021, driven by declining COVID-19 cases.

BioSig Technologies, Inc. (Nasdaq: BSGM) has announced its participation in the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021. During the event, Kenneth L. Londoner, Chairman and CEO, will present a corporate overview, including updates on the rollout of their innovative PURE EP™ System. Over 470 patient procedures have been successfully conducted using this system across seven clinical sites in the U.S. The presentation is scheduled for 11:30 AM Eastern time.

BioSig Technologies (NASDAQ: BSGM) will showcase its PURE EP System at the 26th Annual International Atrial Fibrillation Symposium on January 29, 2021. G. Joseph Gallinghouse, M.D., from the Texas Cardiac Arrhythmia Institute, will present clinical observations from over 470 patient cases. The event is accessible virtually, offering free registration, and aims to highlight advancements in atrial fibrillation technology. Kenneth L. Londoner, CEO of BioSig, expresses gratitude for the opportunity to engage with a broader audience this year.

BioSig Technologies, a medical technology firm, has been featured in EP Lab Digest for its PURE EP™ System, addressing challenges in electrophysiology (EP). The article emphasizes issues like signal loss and inadequate signal-to-noise ratios in EP labs. The PURE EP™ System's advanced technology helps improve signal fidelity, as demonstrated by recent research where 85% of signals were rated as equivalent or superior. CEO Kenneth Londoner noted the importance of this recognition and plans for increased physician collaborations in 2021.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced a partnership with Vuzix® Corporation (NASDAQ: VUZI) to enhance its PURE EP™ System. The collaboration involves deploying Vuzix’s M400 Smart Glasses for remote servicing, facilitating installations and training during COVID-19 restrictions. This initiative aims to improve efficiency and reduce costs for technicians by enabling remote support. The M400 Smart Glasses utilize Qualcomm's Snapdragon XR1 platform, offering advanced features for various applications, potentially elevating the standard of care in the electrophysiology market.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the installation and first patient cases of its PURE EP(tm) System at Memorial Hospital in South Bend, Indiana. The evaluation is led by cardiologists Vinod Chauhan, M.D., and Deepak Gaba, M.D. To date, over 450 cases have been conducted across seven clinical sites. The company has initiated commercial sales of the system, emphasizing the importance of addressing heart rhythm disorders, especially amid the COVID-19 pandemic. BioSig continues to expand its clinical operations in 2021.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced that Kenneth L. Londoner, Chairman and CEO, will present at the Sidoti Winter 2021 Investor Conference on January 13, 2021, at 2:30 PM ET. The presentation will cover company highlights and achievements, including over 410 patient procedures with the PURE EP™ System conducted by 32 electrophysiologists in seven U.S. clinical sites. Interested parties can register for the presentation and one-on-one meetings through provided links.

BioSig Technologies (NASDAQ: BSGM) has announced a collaboration with the University of Minnesota to develop therapies for autonomic nervous system diseases through its NeuroClear Technologies division. This agreement aims to create new hardware, software, and algorithmic solutions for these conditions. The R&D program is expected to commence in Q4 2020 and will be led by esteemed professionals from the university. The partnership signifies a strategic move to enhance BioSig's bioelectronic medicine innovations, potentially fueling product development and FDA approval.

BioSig Technologies announces a significant commercial expansion through the sale of three PURE EP™ Systems to St. David's HealthCare in Austin, Texas. This marks BioSig's first commercial sale, aimed at expanding its installed base nationwide. The PURE EP™ System has already been utilized in over 410 patient procedures across six hospital sites, demonstrating its traction in the electrophysiology market. The company emphasizes the importance of this sale as it strengthens their relationship with St. David’s Medical Center, a recognized leader in healthcare quality.